ERBB2 and breast cancer: In the TH3RESA trial, T-DM1 demonstrated an improved PFS (6.2 months vs. 3.3 months, HR 0.528) and later overall survival compared to the treatment of physician’s choice for patients with HER2+ breast cancer who had already previously received two prior lines of chemotherapy including a taxane in any setting and trastuzumab/lapatinib for an advanced disease [8].